|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Jul. 10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Jul. 10 | Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA | DJ |
| Market Cap | 138B 120B 111B 103B 195B 13,138B 198B 1,328B 521B 6,472B 517B 506B 22,251B | P/E 2026 * |
12.3x | P/E 2027 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 187B 164B 151B 139B 264B 17,840B 269B 1,803B 708B 8,789B 702B 687B 30,213B | EV / Sales 2026 * |
3.03x | EV / Sales 2027 * | 3.05x |
| Free-Float |
59.06% | Yield 2026 * |
7.14% | Yield 2027 * | 7.21% |
Last Transcript: Pfizer Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 64 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 60 | 2022-05-01 |
| Chief Tech/Sci/R&D Officer | - | 2006-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 68 | 2007-08-31 |
Shantanu Narayen
BRD | Director/Board Member | 62 | 2013-09-26 |
Albert Bourla
CHM | Chairman | 64 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.33% | -2.09% | +49.88% | +170.51% | 1,060B | |
| -0.82% | -2.30% | +63.79% | +62.00% | 619B | |
| -0.73% | -4.98% | +28.91% | +82.99% | 438B | |
| +0.33% | -1.17% | +31.07% | +27.09% | 333B | |
| -0.02% | -2.85% | +29.15% | +45.24% | 282B | |
| -3.89% | -11.22% | +22.81% | +27.30% | 267B | |
| +0.66% | -1.42% | -26.59% | -37.71% | 218B | |
| -0.06% | -2.88% | +23.07% | +62.33% | 196B | |
| -3.72% | -1.10% | +18.41% | +70.56% | 161B | |
| Average | -1.18% | -3.25% | +26.72% | +56.70% | 397.1B | |
| Weighted average by Cap. | -1.31% | -2.96% | +36.75% | +83.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 61.75B 54.01B 49.82B 46.01B 87.3B 5,889B 88.77B 595B 234B 2,901B 232B 227B 9,973B | 59.37B 51.93B 47.9B 44.24B 83.94B 5,662B 85.35B 572B 225B 2,789B 223B 218B 9,589B |
| Net income | 10.61B 9.28B 8.56B 7.91B 15B 1,012B 15.26B 102B 40.17B 499B 39.84B 38.98B 1,714B | 10.26B 8.98B 8.28B 7.65B 14.51B 979B 14.75B 98.93B 38.85B 482B 38.53B 37.7B 1,658B |
| Net Debt | 49.3B 43.12B 39.77B 36.73B 69.7B 4,702B 70.88B 475B 187B 2,316B 185B 181B 7,963B | 43.17B 37.76B 34.83B 32.17B 61.04B 4,117B 62.06B 416B 163B 2,028B 162B 159B 6,973B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
